The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.
 
Manuela Salvucci
No Relationships to Disclose
 
Maximilian Wuerstle
No Relationships to Disclose
 
Mattia Cremona
No Relationships to Disclose
 
Sarah Curry
No Relationships to Disclose
 
Clare Morgan
No Relationships to Disclose
 
Andreas Ulrich Lindner
No Relationships to Disclose
 
Orna Bacon
No Relationships to Disclose
 
Alexa Resler
No Relationships to Disclose
 
Aine Murphy
No Relationships to Disclose
 
Daniel Longley
No Relationships to Disclose
 
Richard H. Wilson
Consulting or Advisory Role - Bioven; Merck Serono; Sanofi; Sirtex Medical
Travel, Accommodations, Expenses - Merck Serono
 
Sophie Camilleri-Broët
No Relationships to Disclose
 
Manuel Salto-Tellez
No Relationships to Disclose
 
Deborah A McNamara
No Relationships to Disclose
 
Elaine Kay
Consulting or Advisory Role - Almac Diagnostics
Patents, Royalties, Other Intellectual Property - DCS; Royal College of Surgeons in Ireland
 
Bryan Hennessy
No Relationships to Disclose
 
Pierre Laurent-Puig
Honoraria - Boehringer Ingelheim; Merck Serono; Roche; Sanofi
Consulting or Advisory Role - Boehringer Ingelheim; Merck Serono
Research Funding - Merck Serono
Patents, Royalties, Other Intellectual Property - IntegraGen
Travel, Accommodations, Expenses - IntegraGen; Merck
 
Sandra Van Schaeybroeck
No Relationships to Disclose
 
Markus Rehm
Patents, Royalties, Other Intellectual Property - Patent on “A computer-implemented system and method for the prediction of cancer response to genotoxic chemotherapy and personalised neoadjuvant treatments (pccp)” (Derwent primary accession number: 2013-A25393)
 
Jochen Prehn
Patents, Royalties, Other Intellectual Property - Patent on “A computer-implemented system and method for the prediction of cancer response to genotoxic chemotherapy and personalised neoadjuvant treatments (pccp)” (Derwent primary accession number: 2013-A25393 )